Company Analysis
Sign in

Cellyan Biotechnology Co., Ltd (HKPD)

Nasdaq: HKPD · Wholesale-Drugs, Proprietaries & Druggists' Sundries · filing with the SEC since 2024
Full chart Alerts Compare
Grade5.5
◀ Past 5.5● Present 5.4▶ Future 5.7
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$20.3M+21.7%
Net income-$27,056-102.0%
Earnings per share$-0.00-101.7%
Operating cash flow$569,214+244.3%
Cash$748,721+20.8%
Debt$1.9M+44.3%
Shareholders’ equity$5.0M+17.3%
Shares, diluted10.2M+38.6%
Return on equity-0.5%
The recordfrom its filings
Filings in 202625
Newest filingNov 12 · 6-K
Annual reportAug 7, 2026
Quarterly reportn/a
Next report due20-F by Jul 29
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
232425
As filed, in USD. Nothing here is a forecast.

News

Jun 24, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton HKPD · research, not advice